Certain statements and information contained in this presentation that are not statements or information of historical fact constitute forward-looking statements, notwithstanding that such statements are not specifically identified. These forward-looking statements may include statements regarding our (or our portfolio companies’) plans, objectives, goals, strategies, future events, future revenue or performance, financing needs, plans or intentions relating to acquisitions, investments or capital expenditures, business trends or other information that is not historical information. These statements may include terminology such as “may,” “will,” “expect,” “could,” “should,” “intend,” “estimate,” “anticipate,” “believe,” “remain,” “on track,” “design,” “target,” “objective,” “goal,” “forecast,” “projection,” “outlook,” “prospects,” “plan,” “intend,” or similar terminology. Forward-looking statements are related to future, not past, events and are not guarantees of future performance. These statements are based on current expectations, assumptions and projections about future events and, by their nature, address matters that are, to different degrees, uncertain and are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future, and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including among others:

- changes in general economic, financial and market conditions and other changes in business conditions;
- changes in commodity prices, the level of demand and financial performance of the major industries our portfolio companies serve; and
- changes in regulations and institutional framework (in each case, in Italy or abroad); and
- many other factors, most of which are outside of the control of EXOR.

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in EXOR’s Annual Report 2022, including those set forth under the heading “Risk Factors”. These risks and uncertainties, as well as other risks of which we are not aware or which we currently do not believe to be material, may cause our actual future results to be materially different than those expressed in our forward-looking statements.

Investors and shareholders are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. EXOR undertakes no obligation to update or revise its outlook or forward-looking statements, whether as a result of new developments or otherwise. EXOR expressly disclaims and does not assume any liability in connection with any inaccuracies in any of these forward-looking statements or in connection with any use by any party of such forward-looking statements.

Names, organizations and company names referred to may be the trademarks of their respective owners.

This presentation does not represent investment advice neither a solicitation, nor a recommendation nor an invitation, nor an offer for the purchase or sale of financial products and/or of any kind of financial services as contemplated by the laws in any country or state.
EXOR INVESTOR DAY

AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT’S NEXT?
In 2023 we continued to execute on our priorities

### Companies
- Became a long-term investor in Philips, a global leader in health technology, and built a 15% stake
- Joined forces with Impala to develop TagEnergy, a fast-growing company in the renewal energy space
- Committed to participate in the Juventus capital increase
- Increased investment in Via Transportation

### Investments
- Launched Lingotto as an independent alternative investment manager with $4.5bn AuM contributed by Covéa and Exor
- Continued our investments in Exor Ventures

### Finance
- Announced a new €1bn share buyback program
- Managed our financial position efficiently, with rating upgraded to A- by S&P

### ESG
- Published our first TCFD report
- Expanded our education initiatives
WE HAVE REDEPLOYED THE PARTNER RE SALE PROCEEDS

<table>
<thead>
<tr>
<th>CASH GENERATION¹</th>
<th>2022-24</th>
<th>CASH USES</th>
<th>CASH ALLOCATED⁶</th>
<th>REMAINING CASH</th>
</tr>
</thead>
<tbody>
<tr>
<td>~10.0</td>
<td>3.5</td>
<td>1.7</td>
<td>1.3</td>
<td>~1.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.3</td>
<td>0.6</td>
<td>~1.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.7</td>
<td>~0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

in Euro billion

CASH USES

<table>
<thead>
<tr>
<th>Companies²</th>
<th>Investments³</th>
<th>Buyback</th>
<th>Debt reduction⁴</th>
<th>Others⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>~10.0</td>
<td>3.5</td>
<td>1.7</td>
<td>1.3</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>~1.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>~0.5</td>
</tr>
</tbody>
</table>

1) Including proceeds from the sale of Partner Re, cash and cash equivalents and listed securities at 2021 YE and Net FCF in 2022-24.
2) Including amount invested in Philips, Institut Merieux, TagEnergy, Juventus, Lifenet, Via, Casavo, ShangXia and NUO.
3) Including amount invested in Lingotto Funds and Ventures.
4) Corresponding to €0.6bn maturing bond in December 2022, redeemed in October 2022 pursuant to the pre-maturity call option.
5) Including other assets of which €0.4bn reinsurance vehicles expected to mature after 2024.
6) Including amount allocated to Institut Merieux (€0.55bn), Lingotto Funds (€0.35bn), Ventures (€0.42bn) and the remaining amount allocated to Buyback not yet funded (€0.25bn), among others.

Note: Numbers may not add due to rounding.
AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT'S NEXT?
OUR THREE LARGEST COMPANIES CONTINUE TO PROGRESS ON THEIR STRATEGIC PLANS

**Pushing the Boundaries**
- Net revenues of €4.4bn YTD (+19% vs LY)¹
- Net profit of €1.0bn YTD (+34% vs LY)
- >€0.9bn of Industrial FCF in 2023E
- 2023 guidance raised

**Dare Forward**
- Net revenues of €143.5bn YTD (+10% vs LY)¹
- Global BEV sales +37% (vs Q3 2022)
- Strong Industrial FCF in 2023E
- 2023 guidance confirmed

**Breaking New Ground**
- Revenues² of $17.9bn YTD (+8% vs LY)¹
- Net profit of $1.8bn YTD (+22% vs LY)
- $1.0-$1.2bn of Industrial FCF in 2023E
- 2023 guidance lowered

We will continue to support our Companies as they pursue their paths to greatness

---

¹ YTD refers to the nine months ending on 30 September 2023; LY refers to the equivalent period for 2021. ² Refers to consolidated revenues that include financial services.
WE HAVE CONTINUED TO LOOK FOR NEW COMPANIES IN OUR THREE PRIORITY SECTORS

<table>
<thead>
<tr>
<th>Priorities</th>
<th>Rationale</th>
</tr>
</thead>
</table>
| HEALTHCARE | ▪ A non-cyclical sector with structural tailwinds  
▪ Large sector with significant inefficiencies where we can accelerate innovation  
▪ Technology-enabled healthcare solutions can be highly scalable |
| LUXURY     | ▪ A growing and resilient sector with demographic tailwinds  
▪ Can benefit from our long-term committed capital and experience of family ownership  
▪ Technology is changing the customer connection and supply chain transparency |
| TECHNOLOGY | ▪ Is under-represented in our portfolio and has substantial growth potential  
▪ Our ownership of operating companies makes us attractive partners to related technology companies  
▪ We bring an understanding of high growth companies from our Ventures investments |

We also remain open to new sectors and geographies where we can build great companies with great people
Healthcare expenditure has nearly tripled in value since 2000 to +$9tn and represents ~10% of global GDP

| Healthcare expenditure has nearly tripled in value since 2000 to +$9tn and represents ~10% of global GDP |

Pro capita healthcare expenditure doubled in the last 20 years and is expected to continue rising

| Pro capita healthcare expenditure doubled in the last 20 years and is expected to continue rising |

Growth in healthcare expenditure is expected to continue benefitting from the global ageing population

| Growth in healthcare expenditure is expected to continue benefitting from the global ageing population |

Long-term shareholders are rewarded as all healthcare subsectors outperformed the MSCI World over a multi-decade timeframe

| Long-term shareholders are rewarded as all healthcare subsectors outperformed the MSCI World over a multi-decade timeframe |

**WE HAVE DEEPENED OUR KNOWLEDGE OF HEALTHCARE**

**LONG-TERM SUPPORTING TRENDS**

**AREAS WE ARE EXPLORING:**

- Healthcare Services
- Imaging & Instruments
- Diagnostics
- Life Sciences Tools
- Life Science Ingredients, e.g. genomics and proteomics
- Precision Medicine
- Robotics & Automation
- Al-enabled Medicine
- Biomanufacturing
- Pharma services
Our investment in Philips is our largest healthcare investment

€2.8bn investment  
15% ownership  
Right to nominate 1 Director  
Closed on 14 August 2023

Strong alignment with Philips management team

“Exor’s investment in Philips, their long-term outlook and increased focus on healthcare and technology, fit well with our strategy and substantial value creation potential. With our market leadership positions and people-centric innovation capabilities, Philips is well positioned to deliver on our purpose to improve the health and well-being of people, creating value for all stakeholders.” – Roy Jakobs (Philips CEO)

“We welcome Exor as a long-term investor in Philips. They have a successful track record and clear strategy to grow and develop in healthcare and technology. Exor’s substantial investment underlines their confidence in Philips’ transformation into a healthcare technology company and its growth and value potential.” – Feike Sijbesma (Philips Chair)

“The path of change taken by Philips in recent years has created a company that combines two areas – healthcare and technology – to which we are committed. Our discussions have confirmed the strong and positive alignment between our long-term, supportive approach to our companies and Philips’ ambitious plans under the chairmanship of Feike Sijbesma and the executive team led by Roy Jakobs.” – John Elkann (Exor CEO)
PHILIPS HAS SUCCESSFULLY REPOSITIONED ITSELF IN THE HEALTHCARE DOMAIN, AND IS CURRENTLY MANAGING A SET OF CHALLENGES

SALES (€BN) AND SHARE PRICE EVOLUTION (€)

Sources: CIQ as of 29 November. Notes: 1) Comparable Sales Growth (CSG) guidance as provided by the company in their 3Q ’23 Earnings Call presentation.
PHILIPS IS WELL POSITIONED IN ATTRACTIVE SEGMENTS

**Market Leader**

**Sales Split**

- **Diagnosis & Treatment**
  - Ultrasound 20%
  - Diagnostic imaging 40%
  - Image Guided Therapy 40%
  - Total: €8.9BN

- **Connected Care**
  - Enterprise Informatics 20%
  - Sleep & Respiratory Care 20%
  - Monitoring 60%
  - Total: €5.4BN

- **Personal Health**
  - Mother & Child Care 10%
  - Oral Healthcare 35%
  - Personal Care 55%
  - Total: €3.6BN

**Addressable Market (€BN)**

- 2021: €66
- 2025: €79

- CAGR 5%

**Market Positioning**

- #1 Global in Image-Guided Therapy
- #1 Global in Cardiac Ultrasound
- Top 3 Global in Diagnostic Imaging

- #1 in Hospital monitoring
- #1 in Ambulatory monitoring
- Leader in Enterprise Informatics (#1 in Imaging, PACS & Interoperability)
- #2 Global in Sleep & Respiratory Care

**Notes:**
1) LTM sales and market positioning as provided by Philips in their Investor Presentation of October 2023.
OUR INVESTMENT ENablES US TO EXPAND OUR PRESENCE IN HEALTHCARE

- **In Line With Our Strategy**
  - Largest shareholder in a large-scale public company exposed to both healthcare and technology

- **Operates In Attractive Markets**
  - Leadership position in attractive niche markets as well as growing exposure to informatics

- **Attractive Valuation**
  - Long-term potential at an attractive price

- **Strong Plan**
  - Targets a return to healthy top-line growth and profitability

- **Potential To Be Great**
  - Management team committed to overcoming current difficulties and building a great company
PHILIPS BECOMES THE FOURTH LARGE COMPANY IN OUR PORTFOLIO

<table>
<thead>
<tr>
<th>COMPANIES ~86% of GAV or ~€33.4bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>~ 75% of GAV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INVESTMENTS ~7% of GAV or ~€2.8bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>~ 11% of GAV</td>
</tr>
</tbody>
</table>

### Gross Asset Value (GAV)
- ~€38.8bn

### COMPANIES
- Stellantis
- CNH Industrial
- Philips
- Institut Merieux
- IVECO Group
- VIA
- The Economist
- Welltec
- GEDI Gruppo Editoriale
- tagenergy
- Lifenet Healthcare
- CASAVO

### INVESTMENTS
- Ventures
  - MultiplyLabs
  - PHASE
  - Lithic
  - upway
  - CARS
  - TEKION
  - Qonto
  - Brex
  - Lingotto

### OTHERS
- ~7% of GAV or ~€2.6bn

---

Note: Figures based on market prices as of 23 November.

1) Including: Cash and equivalents (~€0.4bn), Listed securities (~€0.8bn), Reinsurance vehicles and other assets including treasury shares (~€1.4bn).
EXOR INVESTOR DAY

AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT’S NEXT?
WE HAVE INVESTED ~$0.6BN ACROSS A BALANCED VENTURES PORTFOLIO

STAGE EXPOSURE

- Early: 44%
- Late: 56%

SECTOR EXPOSURE

- Mobility: 23%
- Healthcare: 22%
- Fintech: 18%
- Consumer: 13%
- Deeptech: 11%
- Other: 13%

GEOGRAPHIC EXPOSURE

- U.S.: 49%
- EMEA: 43%
- APAC: 7%
- LatAm: 1%

PORTFOLIO COMPOSITION

- Core Positions (10): 41%
- Mid-size Positions: 39%
- Moonshots: 20%

Note: Based on fair market value. Stage exposure based on time of investment. Does not include Vento.
WE HAVE LAUNCHED VENTO: THE ITALIAN CHAPTER OF EXOR VENTURES

<table>
<thead>
<tr>
<th>EARLY-STAGE INVESTING</th>
<th>VENTURE BUILDING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISION</strong></td>
<td></td>
</tr>
<tr>
<td>✔ The most recognized program for early-stage (pre-seed &amp; seed) Italian entrepreneurs</td>
<td>✔ Back the brightest minds to launch ventures</td>
</tr>
<tr>
<td><strong>GOAL</strong></td>
<td></td>
</tr>
<tr>
<td>✔ Invest in 50%+ of the best new companies over the next 10 years</td>
<td>✔ At least five new Vento companies enter the portfolio each year</td>
</tr>
<tr>
<td>✔ Close 100 deals/year (€15mn/year)</td>
<td></td>
</tr>
<tr>
<td><strong>ECONOMICS</strong></td>
<td></td>
</tr>
<tr>
<td>✔ €150k investment for mid single-digit ownership</td>
<td>✔ €80k convertible note with €800k post-money cap</td>
</tr>
<tr>
<td><strong>OUR VALUE PROPOSITION</strong></td>
<td></td>
</tr>
<tr>
<td>✔ Speed: Efficient process</td>
<td>✔ Network: Strong network of mentors, entrepreneurs and top-tier investors</td>
</tr>
<tr>
<td>✔ Brand: High quality investor</td>
<td>✔ Grant: Support Founders to participate full time</td>
</tr>
<tr>
<td>✔ Community: Strong network of founders, top-tier investors, and corporates</td>
<td>✔ Potential investment: Opportunity to receive a pre-seed check</td>
</tr>
<tr>
<td>✔ Global reach: Help founders think globally</td>
<td></td>
</tr>
<tr>
<td><strong>RESULTS</strong></td>
<td></td>
</tr>
<tr>
<td>✔ 2,158 applications since April 2022</td>
<td>✔ 1,000+ applications received in the last 2 cohorts</td>
</tr>
<tr>
<td>✔ 55 companies backed</td>
<td>✔ 20 new companies incorporated, 10 backed by Vento</td>
</tr>
</tbody>
</table>
Introduction to Lingotto

Who We Are

Lingotto is an independent alternative investment manager, that was launched in May 2023, and is wholly owned by Exor

Two Founding investors: Exor and Covéa

~$4.5bn\(^1\) AUM

3 core strategies

~40 investment and business professionals

Offices in London and New York

Our Objective

“We are committed to delivering attractive long-term returns to our limited partners, protecting their capital from permanent losses while accepting concentration, illiquidity and volatility”.

John Elkann
(Founder)

1. AUM as of 30\(^{th}\) September 2023, including commitments. Includes strategies that are not currently open to external investors.
Our Differentiated Approach

Capital
Committed, long-term investors with alignment of interest and shared objectives

People
Experienced, entrepreneurial leaders with proven industry track record

Strategies
Complementary and unique investment philosophies

Risk Management
Acceptance of concentration, illiquidity and volatility
Lingotto Values

Courage & Responsibility
Having conviction in our differentiated analysis whilst embracing concentration and maintaining full accountability

Ambition & Humility
Encouraging diversity of opinion and rigorous thinking, we aim to deliver uncorrelated results

Curiosity & Focus
Appreciating the unexplored and the unconventional, while avoiding short-termism

Patience & Drive
Accepting volatility as an opportunity and not a risk, firmly believing in the benefits of long-term investing

Culture rooted in transparency, autonomy and cooperation
Strategies and Managing Partners/CIOs

~$4.5bn\(^1\) Assets Under Management Today

**LONG/SHORT EQUITY**
Matteo Scolari
- 20 years investment experience
- Former Eton Park Portfolio Manager
- Goldman Sachs and McKinsey
- Wharton MBA, Palmer Scholar

**Strategy:** Public equity, on concentrated long only and long/short basis
**Investment approach:** Fundamental bottom-up approach, long-term analysis, concentrated portfolio
**Geography:** Predominantly developed markets

**NAV** ~$2,400m\(^1\)

**OPPORTUNITY**
Nikhil Srinivasan
- 20 years investment experience
- Former CIO: Allianz, Generali, PartnerRe
- Twice supervised ~$500bn in assets

**Strategy:** Investments across the full capital structure, mostly in private companies
**Investment approach:** Special situation opportunities in idiosyncratic niches
**Geography:** Global with a bias to Europe & Asia

**NAV** ~$1,600m\(^2\)

**INNOVATION**
James Anderson
- 40 years investment experience
- Partner Baillie Gifford (1987 - 2022)
- Former co-manager Vanguard Intl Growth Fund & Scottish Mortgage Investment Trust.
- Chair of Kinnevik AB

**Strategy:** Primarily public equity with some private equity, on a long-only basis
**Investment approach:** Identifying rare structural winners, concentrated, long-term commitment
**Geography:** Global

**NAV** ~$500m\(^1\)

---

1. As of 30\(^{th}\) September 2023, including commitments.
2. As of 30\(^{th}\) June 2023. Includes strategies that are not currently open to external investors.
Strategic and Operational Progress

**Progress in 2023…**

**STRATEGIES**
- ‘Opportunity’ launched in Q1 2023
- ‘Innovation’ launched in Q2 2023

**PEOPLE**
- New joiners - Investment Teams
  - Managing Partner and CIO, Partners and Analysts
- New joiners - Business
  - COO, Investor Relations, Trading and Operations
- Board of Directors - George Osborne appointed as Chair
- Offices - New locations in London and New York

**INVESTORS**
- Engaged prospective investors

**Future Priorities**
- Launch new strategies selectively
- Continue to recruit high quality talent
- Enhance the organization while minimising bureaucracy
- Expand global presence of our investment teams
- Build long-term partnerships with selected investors
AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT’S NEXT?
WE HAVE CONTINUED TO DELIVER ON OUR TARGETS

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>Our Targets</th>
<th>2023YTD(^1)</th>
<th>Last 5 years(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAV/Share growth %</td>
<td><strong>Outperform MSCI World Index</strong></td>
<td>~28% vs. MSCI: ~13%</td>
<td>~63% vs. MSCI: ~51%</td>
</tr>
<tr>
<td>TSR CAGR %</td>
<td>8%</td>
<td>~32%</td>
<td>~8%</td>
</tr>
<tr>
<td>EXOR KPIs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FCF(^3)/ Dividend paid</td>
<td><strong>Above 1.0x</strong></td>
<td>~7.0x</td>
<td>~3.0x</td>
</tr>
<tr>
<td>Holding cost(^4) / GAV</td>
<td><strong>Below 10bps</strong></td>
<td>~7bps</td>
<td>~6bps</td>
</tr>
<tr>
<td>Loan To Value ratio %</td>
<td><strong>Below 20%</strong></td>
<td>~10%</td>
<td>~8%</td>
</tr>
</tbody>
</table>

---

1) As of 23 November. KPI figures related to FCF and holding cost are annualized.
2) Last 5 years as presented in the November 2022 presentation.
3) FCF defined as dividend inflow – net general expenses – net financial income (expenses).
4) Cash based holding cost.
WE ARE DISCIPLINED IN HOW WE ALLOCATE CAPITAL WHILE ENSURING A STRONG BALANCE SHEET AND A STABLE DIVIDEND

<table>
<thead>
<tr>
<th>Companies</th>
<th>Investments</th>
<th>Buyback</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Invest in existing companies</td>
<td>• Invest in Ventures, with exposure to early and late-stage opportunities</td>
<td>• Invest in our own shares when terms are attractive</td>
</tr>
<tr>
<td>• Acquire new companies that have the potential to become great</td>
<td>• Invest in Lingotto Funds, with exposure to public and private market strategies</td>
<td></td>
</tr>
<tr>
<td>• Consider company exits if we are no longer the best owner</td>
<td>• Assess allocation to Investments</td>
<td></td>
</tr>
</tbody>
</table>

We use a Portfolio Review Process to monitor and assess our portfolio and drive capital allocation decisions.
WE HAVE TAKEN ADVANTAGE OF OUR DISCOUNT TO NAV TO INVEST IN OUR PORTFOLIO

- New share buyback program of €1bn announced in September, bringing total share buyback to €1.5bn between 2022 and 2024
- Tender offer for an amount of €750mn launched on 14 September
  - Oversubscribed and priced at zero premium to reference price
  - Acquired shares represented 3.8% of share capital
- Share cancellation process of 5.6% of share capital\(^1\) has started, with effective cancellation in H1 2024
- Regular on-market buyback for the remaining €250mn to continue in 2024

\(^1\) Including 8.87mn shares acquired in the tender offer and other 4.1mn ordinary shares held in treasury.

Buybacks are an integral part of our capital allocation framework
WE FOCUS ON EFFICIENT DEBT MANAGEMENT, SUPPORTED BY A RATING UPGRADE TO A-

### Breakdown

- **Solid capital structure, with Exor’s rating recently upgraded by S&P**
- **Majority in Euro (~95%) and made up of bonds with average maturity ~6 years and average fixed cost ~2.5%**
- **Constant efforts to balance financing across different sources, maturity profiles and amounts**

### Current Gross Debt

- **~€3.7bn**

### Breakdown

- **Public bonds (48%)**
- **Private placements (45%)**
- **Bank debt (7%)**

### Well Balanced Maturity Profile

- **All figures are expressed in millions and in the original currency of issuance**

---

1) Including bond debt and bank debt, excluding other financial liabilities (~€0.6bn).
2) Excluding accrued interest and amortized cost.
3) Exor put in place a cross-currency swap on the bond issue.
EXOR INVESTOR DAY

AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT’S NEXT?
WE ARE CONTINUING TO MAKE SIGNIFICANT PROGRESS AROUND OUR ESG PASSIONS

<table>
<thead>
<tr>
<th>OUR PASSIONS</th>
<th>COMMITMENTS AT HOLDING LEVEL</th>
<th>OUR PROGRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVIRONMENT</td>
<td>Achieve carbon neutrality by 2022 and net zero emissions by 2025</td>
<td>✓ Published our first TCFD Report</td>
</tr>
<tr>
<td>SOCIAL</td>
<td>Reduce the gender gap in STEM subjects</td>
<td>✓ Carbon neutral since FY2021</td>
</tr>
<tr>
<td></td>
<td>Help high potential young entrepreneurs</td>
<td>✓ Working with Innovation 4 Change to support the entrepreneurs of the future</td>
</tr>
<tr>
<td>GOVERNANCE</td>
<td>Maintain 40/60 gender balance and consider diverse candidates for all new appointments</td>
<td>✓ Carried out first unconscious bias training workshop for all employees</td>
</tr>
</tbody>
</table>

We have continued to expand our networks of excellence and knowledge-sharing across our Companies
IN 2023, WE SCALED UP OUR MATABÌ INITIATIVE THAT AIMS TO REDUCE THE GENDER GAP IN STEM SUBJECTS

**Understanding Matabì**

**Aim:** Reduce the gender gap in STEM subjects

**Audience:** Primary school pupils & teachers

**Activities:** Classroom activities using Lego-Duplo kits & teacher training

---

**What Have We Been Building In 2023/24?**

**National Rollout**

- Publicly launched in Naples
- 130 classes from 25 schools in 6 Italian regions
- Special impact assessment framework
- Roadshow on the role of women in STEM

---

*Matabi is carried out by Fondazione Agnelli*

*Other partners:*

- The LEGO Foundation
- Pubblica Scuola di Torino
- CRESS
- Lab competenze di startup
AGENDA

- UPDATE
- COMPANIES
- INVESTMENTS
- FINANCIALS
- ESG
- WHAT’S NEXT?
WE WILL CONTINUE TO FOCUS ON OUR PRIORITIES

- Remain a long-term and active shareholder, aligning ownership, governance and leadership
- Strengthen our investment capabilities through Exor Ventures and Lingotto
- Continue to explore new opportunities
- Maintain discipline in capital allocation, while ensuring a strong balance sheet
Mediocrity is not worth the trip.

Sergio Marchionne
EXOR INVESTOR DAY

Q&A SESSION